BDTX

Black Diamond Therapeutics, Inc.

6.12 USD
-0.12 (-1.92%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Black Diamond Therapeutics, Inc. stock is up 6.62% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 June’s closed higher than May. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
02 May 14:40 21 Jun, 2024 7.50 CALL 5000 167
06 Jun 19:40 20 Sep, 2024 7.50 CALL 629 181

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. discovers, develops, and commercializes medicines for patients with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by non-canonical epidermal growth factor receptor (EGFR) mutations. The company is also developing a brain-penetrant inhibitor of EGFR mutations.

  • HC Wainwright & Co.
    Fri Jun 7, 07:16
    buy
    confirm
  • HC Wainwright & Co.
    Thu May 16, 07:35
    buy
    confirm